CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
cetuximab (Erbitux) +3 moredrug
Likely dose
cetuximab (Erbitux) 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00815308
NCT00815308Phase 2Completed

An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Shandong Cancer Hospital and Institute·interventional·Posted Dec 30, 2008·Updated Feb 8, 2011

In Brief

A Phase 2 clinical trial evaluating cetuximab (Erbitux), Paclitaxel, and 2 other interventions for Esophageal Cancer. Completed, enrolled 55 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the treatment of locally advanced esophageal squamous cell carcinoma (ESCC)with cetuximab in combination with paclitaxel, cisplatin and radiation improve clinical outcomes.

Study Details

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 30, 2008
Enrollment StartJan 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.5 years ago

Interventions

cetuximab (Erbitux)drug

Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)

Paclitaxeldrug

Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)

Cisplatindrug

Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)

Radiationradiation

Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).